Skye Bioscience, Inc. (SKYE)
Data as of , from SEC Form 4 filings.
See up to 3 months of SKYE. The 7-day demo opens the 1M and 3M ranges and puts SKYE on your watchlist.
Start 7-day demoLatest SKYE insider trades
Andrew J. Schwab - DirectorOpen-market sale$46K- Andrew J. Schwab - DirectorOpen-market sale$2K
About Skye Bioscience, Inc. (SKYE)
The SEC lists Skye Bioscience, Inc. under CIK 0001516551, in pharmaceutical preparations. It is grouped with Health Care companies on this site.
SKYE Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 30 | 1,115,622 | $889K |
| Grant or award | 1 | 1,090,000 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
SKYE insider transactions (Form 4)
1039 Form 4 filings on record, the earliest from Oct 30, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Punit Dhillon - Officer | Open-market sale | Common Stock | 364 | $5.55 | $2K | |
| Punit Dhillon - Officer | Open-market sale | Common Stock | 82,546 | $4.99 | $412K | |
| Tuan Tu Diep - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Kaitlyn Arsenault - Officer | Grant or award | Stock Option (Right to Buy) | 125,000 | $0.00 | - | |
| Andrew J. Schwab - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Paul A. Grayson - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Karen L. Smith - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Deborah H. Charych - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Annalisa Jenkins - Director | Grant or award | Stock Option (Right to Buy) | 70,000 | $0.00 | - | |
| Punit Dhillon - Officer | Grant or award | Stock Option (Right to Buy) | 650,000 | $0.00 | - |
SKYE insider trading FAQ
What is the latest insider trade for SKYE?
Skye Bioscience, Inc. (SKYE) had 7 insider filings in the last 90 days, with the most recent on 2026-09-24. The full record for SKYE runs to 39 Form 4 filings, the earliest from 2024-10-30. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying SKYE stock?
No insider purchases of SKYE were filed in the last 90 days.
How many insiders are selling SKYE stock?
30 insider sales of SKYE were filed in the last 90 days, totaling $889K.
Where can I see SKYE SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects SKYE Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Andrew J. Schwab view on EDGAR
- - 5AM Partners VII, LLC view on EDGAR
- - Andrew J. Schwab view on EDGAR
- - 5AM Partners VII, LLC view on EDGAR
- - Andrew J. Schwab view on EDGAR
- - 5AM Partners VII, LLC view on EDGAR
- - Punit Dhillon view on EDGAR
- - Karen L. Smith view on EDGAR
- - Christopher Twitty view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Insider activity in Health Care
- Where SKYE's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow SKYE with a 7-day demo
- SKYE on your watchlist
- Every SKYE Form 4 filing on record
- Up to 3 months of SKYE price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
